Kornimate/medical-research-clean huggingface dataset:
butyrate/hexanoate in metabolic health

Conditions: Metabolic Disease

Summary: in this study, we aim to identify a well consumable butyrate/hexanoate-enriched oil that increases circulating scfa concentrations and improves postprandial substrate metabolism, which could be further used for a long-term study.


Eligibility criteria:
inclusion criteria * overweight/obese men (bmi ≥ 25 kg/m2 and ≤ 34.9 kg/m2); * aged 40 - 70 years; * caucasian; * normal blood pressure (systolic blood pressure 100-140mmhg, diastolic blood pressure 60-90 mmhg); * weight stable for at least 3 months (± 2 kg). exclusion criteria * type 2 diabetes mellitus (defined as fasting plasma glucose ≥ 7.1 mmol/l) * gastroenterological diseases or abdominal surgery (gallbladder removal and appendix removal are allowed) * cardiovascular diseases, cancer, liver or kidney malfunction, disease with a life expectancy shorter than 5 years; * lactose intolerance or other disorders that affect digestion (such as celiac disease) * abuse of products; alcohol and drugs, excessive nicotine use defined as \>20 cigarettes per day; and excessive alcohol use defined as (\> 15 units/week) * plans to lose weight or following of a hypocaloric diet in the following three months; * regular supplementation of pre- or probiotic products (for example yakult, activia), use of pre- or probiotics 3 months prior to the start of the study; * intensive exercise training more than three hours a week; * use of any medication that influences glucose or fat metabolism and inflammation (i.e. betablockers, corticosteroids, statins or nsaids); * regular use of laxation products in 3 months prior start of study or during study period; * use of antibiotics in the last three months (antibiotics use can alter substantially the gut microbiota composition). * follow a vegan diet or vegetarian diet.
real-world research : assessment of effect of combination of drugs in the treatment of heart failure

Conditions: Heart Failure

Summary: the goal of this observational study is to assess the effect of the different combination of drugs in the treatment of heart failure. the main questions it aims to answer are: * \[question 1\] the changes of bnp and lvef in patients of each groups with different drugs co-administration. * \[question 2\] the days of hospitalization, degree of lower limb edema (mild, moderate, severe) and 6-minute walking test in each groups. participants will be asked to do nothing. all the records of the patients will be download from the big data cloud platform of health care in the first affiliated hospital of shandong first medical university. there is not a comparison group.

the purpose of this study is to evaluate the efficacy and cost-effective of different drugs co-administration in the treatment of heart failure. for different reasons, patients with heart failure took different drug prescriptions. now there are five kinds of drugs for the treatment of heart failure, such as angiotensin converting enzyme inhibitor or angiotensin receptor blocker (acei/arb), beta-blokers, spironolactone, sodium-glucose cotransporter (sglt) 2 inhibitors and vericiguat. our purpose is to assessment the efficacy and cost-effective of different drugs co-administration in the treatment of heart failure.

Eligibility criteria:
inclusion criteria: * patients diagnosed as "heart failure" or "cardiac insufficiency" on the first page of the medical record exclusion criteria: * severe impairment of liver, kidney and lung function (transaminase increased more than 2 times; scr \> 265umol/l); malignant tumor
t cell receptor based therapy of metastatic colorectal cancer

Conditions: Colorectal Cancer

Summary: t cell receptor based therapy of metastatic colorectal cancer with mrna-engineered t cells targeting transforming growth factor beta receptor type ii (tgfβii)

patients with advanced metastatic colorectal cancer who have no other effective treatment options will be offered the treatment. these patients have a poor prognosis, and there is a strong need for improved therapy. the patients will be given adoptive cell therapy (act) with radium-1 tcr+ t cells transiently redirected against the tgfβrii frameshift antigen which is expressed in msi+ colon cancer. the first report on tcr therapy in colon cancer was targeting carcinoembryonic antigen (cea) where some evidence of clinical response was seen, but the t-cell function may have been inhibited due to the necessity to resolve the severe colitis which occurred due to the presence of cea in normal cells in the colon. this demonstrates the feasibility of t-cell therapy in metastatic colon cancer, but also the limitations of targeting cea as an antigen.

Eligibility criteria:
inclusion criteria: * patients with metastatic colon cancer which is msi+ with the presence of the -1a deletion in tgfβrii gene, and positive for hla-a02 genotype * measurable disease * female or male patients. fertile females must have a negative pregnancy test before inclusion in the trial. both fertile men and women must be ready and able to use highly effective methods of contraception, defined as use of oral, implanted, injectable, and mechanical or barrier products for the prevention of pregnancy during participation of the trial * eastern cooperative oncology group (ecog) performance score of 0 to 1 * age 18 years and older * life expectancy of at least 3 months * signed informed consent (by the subject or subject's legal representative) obtained before any trial-related procedures. * adequate organ function, measured by pre-defined laboratory values exclusion criteria * other metastatic malignancies * any other anti-tumour treatment within 4 weeks prior to first administration of cells. * steroid treatment, except substitution dose * significant cardiac or other medical illness that would limit activity or survival, such as severe congestive heart failure, unstable angina or serious cardiac arrhythmia * active infection requiring antibiotic therapy * pregnancy or lactation * known hypersensitivity to any of the components of the investigational product * patients who test positive for hepatitis b, c, hiv or syphilis * any reason why, in the opinion of the investigator, the patient should not participate

Keywords: msi
smyls: a self-management program for youth living with sickle cell disease

Conditions: Sickle Cell Disease

Summary: the purpose of this study is to find out whether a web-based intervention using a mobile device is helpful for teens learning to care for and manage symptoms of sickle cell disease. the intervention lasts 12 weeks with a 3-month follow up period, and uses a smartphone or a tablet.

the purpose of the proposed study is to test the feasibility of smyls, an mhealth intervention designed to facilitate self-management behaviors in children and adolescents with sickle cell disease (scd). specifically, the investigators propose to test the feasibility of the intervention for improving transition from parent-managed to adolescent self-managed care. in addition, the investigators will evaluate the communication that takes place via the intervention between adolescents, their parents/caregivers, and healthcare providers. the investigators will work with the musc pediatric sickle cell clinic to identify and recruit 5 healthcare providers of children with scd and 30 dyads of adolescents ages 11 - 17 scd and their parent/caregiver (n = 60).

Eligibility criteria:
inclusion criteria: * diagnosis of scd as reported by provider * self-reported history of pain at least once per month * caregiver/parent willingness to participate * owns a smartphone exclusion criteria: * not under the care of a provider participant * cognitive disability or delay that precludes ability to participate, defined as classified severe neurocognitive deficits as documented by neuropsychological evaluation in the medical record * lack of wi-fi access
effects of tai chi on postural balance and quality of life in the elderly with gait disorder

Conditions: Gait Disorder; Postural Balance

Summary: the goal of this intervention study was to test balance ability and quality of life in older adults with gait problems. the main questions it aims to answer are: 1. can the balance ability of elderly people with gait disorders be improved through tai chi intervention? 2. whether tai chi intervention can improve the quality of life of elderly people with gait disorders. participants will be divided into an experimental group and a control group. the experimental group will undergo 12 weeks of tai chi intervention, while the control group will maintain daily habits, including simple walking or stretching activities.

the inclusion criteria for potential participants were as follows: age ≥ 60 years old have mild gait problems can walk independently no tai chi training experience or exercise habits the exclusion criteria for potential participants were as follows: age \<60 years old no obvious problems with gait walking with tools have experience in tai chi intervention within three months hearing loss outcomes measured: balance, gait, muscle strength, mobility, fall rate, quality of life.

Eligibility criteria:
inclusion criteria: * age ≥ 60 years old have mild gait problems can walk independently no tai chi training experience or exercise habits exclusion criteria: * age \<60 years old no obvious problems with gait walking with tools have experience in tai chi intervention within three months hearing loss

Keywords: tai chi balance gait quality of life muscle strength
development of a self-collection device for cervical cancer screening

Conditions: Human Papilloma Virus Infection Type 16; Human Papilloma Virus Infection Type 18; Human Papilloma Virus

Summary: evaluation of a novel self-collection device for cervical cancer screening.

the purpose of this study is to collect design and user input on the safety and effectiveness of the teal health self-collection device for patient self-collection of cervicovaginal samples for use with fda-approved in vitro diagnostics indicated for high risk human papillomavirus (hrhpv) screening.

Eligibility criteria:
inclusion criteria: group 1: inclusion criteria - general population group 1. subject is 25 to 65 years of age and willing to provide informed consent. 2. subject with intact cervix. group 2: inclusion criteria - hpv positive population group (hpv+ enriched group) 1. subject is 25 to 65 years of age and willing to provide informed consent. 2. subject with intact cervix. 3. prior diagnosis of high risk hpv and/or positive cytology and/or presenting for colposcopy. exclusion criteria: 1. subject who reports current menstruation. 2. subject is pregnant (based on self-reporting). 3. subject has impaired decision-making capacity or unable to provide informed consent. 4. subject is participating in another clinical study for an investigational device, drug, or biologic that, in the investigator's opinion, would interfere with the results of this study. 5. subject has undergone partial or complete hysterectomy including removal of the cervix. 6. subject has applied any chemical compounds to the cervical area within the 24-hours prior to study sample collection, including iodine, spermicide, douche, anti-fungal medications, generally, and specifically: replens vaginal moisturizer and rephresh vaginal hygiene products. 7. subject on whom any form of cervical tissue alteration or surgery has been performed within the prior year, including: conization, loop electrosurgical excision procedure (leep), laser surgery, or cryosurgery.

Keywords: cervical cancer screening high risk hpv hrhpv
outcomes for manual lymphatic drainage

Conditions: Total Knee Arthroplasty

Summary: in this context, the purpose of our study is to investigate the effect of mld(manual lymphatic drainage) technique applied in addition to the standard postoperative rehabilitation protocol on pain, kinesophobia and quality of life in early periods in patients undergoing primary tka(total knee arthroplasty) surgery. our hypothesis is that the addition of the mld technique to the standard postoperative rehabilitation protocol will improve the early clinical outcomes of patients undergoing primary tka. in the future perspective, we anticipate that the data obtained as a result of our study will make a significant contribution to the relevant literature on the early and mid-term ameliorative effects of mld on postoperative pain, kinesiophobia and quality of life, which will be possibly applied in addition to standard postoperative rehabilitation protocols in patients undergoing primary tka.


Eligibility criteria:
inclusion criteria: * patients between the ages of 40-85 * were diagnosed with stage iv gonarthrosis * planned primary total knee arthroplasty (tka) * were evaluated before the operation * whose informed consents exclusion criteria: * patients with postoperative pulmonary thromboembolism or treatment-related complications in the past, * patients with osteoarthritis secondary bone or joint infections, * patients with morbid obesity, * patients with presence of hematological disease and malignancy, * major cardiac pathology, * venous insufficiency, * patients taking high-dose anticoagulants * patients with communication problems

Keywords: total knee arthroplasty manual lymph drainage kinesiophobia pain quality of life
effect of valsartan on left ventricular myocardial functions in hypertensive patients with left ventricular hypertrophy

Conditions: Hypertension; Left Ventricular Hypertrophy

Summary: the study hypothesis: valsartan as an angiotensin ii receptor blocker treatment has beneficial effects on both midwall mechanics and myocardial functions in hypertensive patients with left ventricular hypertrophy.


Eligibility criteria:
inclusion criteria: * hypertension with left ventricular hypertrophy exclusion criteria: * clinical or laboratory evidence of secondary hypertension * heart failure * ischemic heart disease * valvular heart disease * arrhythmias * peripheral vascular disease * chronic obstructive pulmonary disease * neurologic disorders * diabetes mellitus * renal dysfunction * notable systemic disease

Keywords: hypertension left ventricular hypertrophy angiotensin receptor blocker midwall mechanics tissue doppler imaging hypertension with left ventricular hypertrophy
the effect of a gastric bypass on type 2 diabetes in the morbidly obese patient

Conditions: Type 2 Diabetes; Morbid Obesity

Summary: proof of concept, of rygbp and its capabilities to cure type 2 diabetes (dm 2) and sleep apnea has already been recognized in the reports on weight loss surgery. the investigators project aims to prove that rygbp also recovers the beta cell function (bcf) clamp tests, the gold standard for testing is and bcf, will be performed preoperative and early postoperatively. aims \& methodology: analysis of the short-term effect of gastric bypass and sleeve gastrectomy on insulin sensitivity and beta cell function. preoperative baseline insulin sensitivity and beta cell function will be assessed with euglycemic and hyperglycemic clamp tests. these results will be compared with the results of the same tests carried out 3 weeks postoperative. to determine if the duodenal exclusion is causing this effect. the results of the clamp tests 3 weeks postoperative will be compared


Eligibility criteria:
inclusion criteria: * female or male subjects aged 18 to 65 * bmi \> 35 kg/m2 * subject is capable and willing to give informed consent. * in the surgical groups indication for surgery is approved by the local multidisciplinary obesity workgroup following the nih guidelines of 199112. * patient suffers from type 2 diabetes necessitating insulin therapy. * subject is a non-smoker for at least 6 months prior to study start. * female patients of child bearing potential must use oral, injected or implanted hormonal methods of contraception from at least the commencement of their last normal period prior to the screening visit. patients using hormonal contraception should use a barrier method in addition from screening visit until their next normal period following the end of the study. * female patients of non-child bearing potential defined as: * post-menopausal females, being amenorrhoeic for at least 1 year * pre-menopausal females with a documented hysterectomy or bilateral oophorectomy. exclusion criteria: * female patient is pregnant or breastfeeding. * bmi \< 35 kg/m2 * patient suffers from an endocrine disease, besides diabetes and thyroid disease, such as cushing's disease, addison's disease, hypothalamic tumor...) * patient suffers from type 1 diabetes, mody or lada * patient has undergone previous surgical procedure for weight loss * patient is considered asa 4 or more according to the asa physical status classification system of the american society of anesthesiologists. * patient suffers from liver cirrhosis * patient uses steroids * patient uses cyclosporin * recent (\<30 days) or simultaneous participation in another clinical trial. * any situation that can compromise the study, including serious illness or a predictable lack of cooperation from the subject.

Keywords: type 2 diabetes gastric bypass sleeve gastrectomy clamp study weight loss surgery
a study to assess safety of relatlimab with ipilimumab in participants with advanced melanoma who progressed on anti-programmed cell death protein 1 (anti-pd-1) treatment

Conditions: Melanoma

Summary: the primary purpose of this study is to characterize the safety, tolerability, and dose-limiting toxicities (dlts) of relatlimab in combination with ipilimumab.


Eligibility criteria:
inclusion criteria: * must have documented progression while on a prior anti-programmed cell death protein 1 (pd-1) containing regimen limited to nivolumab or pembrolizumab * must have histologically confirmed advanced unresectable (stage iii) or metastatic (stage iv) melanoma, as per (ajcc) staging system * tumor tissue from an unresectable or metastatic site of disease must be provided for biomarker analyses * eastern cooperative oncology group (ecog) 0-1 exclusion criteria: * history of uveal melanoma * known history of positive test for human immunodeficiency virus (hiv) or known acquired immunodeficiency syndrome * prior treatment with ipilimumab, relatlimab, or any other cytotoxic t-lymphocyte-associated antigen 4 (ctla-4) or lymphocyte-activation gene 3 (lag-3) targeted agents
liquid biomarker study in melanoma and non-melanoma skin cancers

Conditions: Skin Cancer; Melanoma (Skin Cancer); Basal Cell Carcinoma of Skin; Basal Cell Carcinoma of Skin, Site Unspecified; Cutaneous Squamous Cell Carcinoma (CSCC); Merkel Cell Carcinoma of Skin

Summary: the goal of this observational study is to study blood samples and compare them to other biospecimens and clinical outcomes in participants who have melanoma or non-melanoma skin cancers. the main question it aims to answer is: * are blood based signatures able to predict progression-free survival (pfs)? participants undergoing regular treatment for their skin cancer will provide blood samples.

this observational study is being done to identify possible biomarkers that can be used for prognostic, prediction, or monitoring considerations in patients with melanoma or non-melanoma skin cancer undergoing treatment. investigators plan to investigate blood factors which include circulating tumor cells (ctcs - i.e., cancer cells that can be detected in the blood) and their associated protein and mrna expression; circulating tumor dna (ctdna - i.e., pieces of dna from cancer cells that can be found in the blood); and tumor-derived exosomes (i.e., extracellular vesicles generated by cancer cells that carry nucleic acids, proteins, and metabolites).

Eligibility criteria:
inclusion criteria: * age ≥18 years. * participants must meet at least one of the following criteria: * finding suspicious of melanoma or non-melanoma skin cancer based on clinical, radiographic, or laboratory findings. non-melanoma skin cancers include: basal cell carcinoma, cutaneous squamous cell carcinoma, and merkel cell carcinoma. * a confirmed diagnosis of melanoma or non-melanoma skin cancer. exclusion criteria: * vulnerable populations, including pregnant women, those who lack consent capacity, the mentally ill, prisoners, cognitively impaired persons, children (age \&lt;18), and uw employees that report to the investigator(s) or to study team members. * not suitable for study participation due to other reasons at the discretion of the investigators.
remote microphone (rm) - a comparative study

Conditions: Hearing Loss, Conductive

Summary: the purpose of this investigation is to evaluate objective outcomes in pediatric bone conduction hearing device (often termed "baha") users with and without remote microphone (rm) technology. in this study, two remote microphone technologies will be evaluated to determine benefit in speech understanding in noise.


Eligibility criteria:
pediatric rm technology group: inclusion criteria: * english speaking pediatric conduction device users and their guardian/s will be included for study. * we will include pediatric patients 5 years of age to 17 years of age who have a conductive or mixed unilateral or bilateral hearing loss with a minimum of a 30 decibels (db) air-bone gap. exclusion criteria: - participants who do not meet the described inclusion criteria. normal hearing controls: inclusion criteria: * adults greater than18 years of age. * hearing thresholds \< 25 db 500 - 4,000 hz. exclusion criteria: - non-english speakers.
high-dose dexamethasone versus conventional dose prednisone for initial treatment of primary immune thrombocytopenia (itp)

Conditions: Purpura, Thrombocytopenic, Idiopathic

Summary: the project was undertaking by qilu hospital of shandong university and other 11 well-known hospitals in china. in order to report the efficacy and safety of high-dose dexamethasone compared to conventional dose prednisone for the first-line treatment of adults with primary immune thrombocytopenia(itp).

the investigators are undertaking a parallel group, multicentre, randomised controlled trial of 300 adults with itp from 11 medical centers in china. part of the participants are randomly selected to receive high-dose dexamethasone treatment and the other part are selected to receive conventional dose of prednisone treatment. platelet count, bleeding and other symptoms were evaluated before and after treatment. adverse events are also recorded throughout the study. in order to report the efficacy and safety of high-dose dexamethasone compared to conventional dose prednisone for the first-line treatment of adults with itp.

Eligibility criteria:
inclusion criteria: 1. meet the diagnostic criteria for immune thrombocytopenia. 2. untreated hospitalized patients, may be male or female, between the ages of 18 \~ 80 years. 3. to show a platelet count \<30 \* 10\^9/l, and with bleeding manifestations. 4. willing and able to sign written informed consent. exclusion criteria: 1. received chemotherapy or anticoagulants or other drugs affecting the platelet counts within 3 months before the screening visit. 2. received second-line itp-specific treatments (eg, cyclophosphamide, 6-mercaptopurine, vincristine, vinblastine, etc) within 3 months before the screening visit. 3. received high-dose steroids or ivig in the 3 weeks prior to the start of the study. 4. current hiv infection or hepatitis b virus or hepatitis c virus infections. 5. severe medical condition (lung, hepatic or renal disorder) other than chronic itp. unstable or uncontrolled disease or condition related to or impacting cardiac function (e.g., unstable angina, congestive heart failure, uncontrolled hypertension or cardiac arrhythmia) 6. female patients who are nursing or pregnant, who may be pregnant, or who contemplate pregnancy during the study period. 7. have a known diagnosis of other autoimmune diseases, established in the medical history and laboratory findings with positive results for the determination of antinuclear antibodies, anti-cardiolipin antibodies, lupus anticoagulant or direct coombs test. 8. patients who are deemed unsuitable for the study by the investigator.

Keywords: purpura, thrombocytopenic, idiopathic